Member access

4-Traders Homepage  >  Shares  >  Nyse  >  AbbVie Inc    ABBV   US00287Y1091

ABBVIE INC (ABBV)

64
 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
62.83(c) 63.1(c) 61.85(c) 63.12(c) 60.35(c) Last
8 181 088 6 532 303 6 910 126 8 485 561 17 520 956 Volume
+0.64% +0.43% -1.98% +2.05% -4.39% Change
More quotes
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis... 
Sector
Pharmaceuticals
Calendar
01/30Earnings Release
More about the company
Surperformance© ratings of AbbVie Inc
Trading Rating : Investor Rating :
More Ratings
Chart ABBVIE INC
Duration : Period :
AbbVie Inc Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 23 410 M
EBIT 2015 9 299 M
Net income 2015 7 030 M
Debt 2015 5 111 M
Yield 2015 3,26%
Sales 2016 25 105 M
EBIT 2016 10 428 M
Net income 2016 7 637 M
Debt 2016 546 M
Yield 2016 3,51%
PER 2015 14,07
PER 2016 12,30
EV / Sales 2015 4,33x
EV / Sales 2016 3,85x
Capitalization 96 165 M
More Financials
Latest news on ABBVIE INC
01/30 ABBVIE : breakup with Shire torpedoes 4th quarter, 2014 results
01/30DJAbbVie Hepatitis C Drug Predictions Disappoint -- Update
01/30 ABBVIE : breakup with Shire torpedoes fourth quarter, 2014 results
01/30DJAbbVie Hepatitis C Drug Predictions Disappoint
01/30 Drugmaker AbbVie beats estimates as Humira sales rise
01/30DJAbbVie Tops Expectations, Gives First Look at Viekira Sales
01/30 SHIRE : AbbVie reports better-than-expected 4Q on Humira sales
01/30 ABBVIE : Results of Operations and Financial Condition, Financial Statements and..
More news
Sector news Biopharmaceuticals
09:15a JOHNSON & JOHNSON : Former FDA chief calls J&J misleading on Risperdal
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
01/30 ABBVIE : breakup with Shire torpedoes 4th quarter, 2014 results
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF